NaPi2b-targeted antibody-drug conjugates and methods of use thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10947317
APP PUB NO 20170266311A1
SERIAL NO

15457574

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MERSANA THERAPEUTICS INC840 MEMORIAL DRIVE CAMBRIDGE MA 02139

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bergstrom, Donald A Winchester, US 8 11
Bodyak, Natalya D Brookline, US 24 298
Lowinger, Timothy B Carlisle, US 96 2039
Park, Peter U Lincoln, US 39 468
Poling, Laura L Boston, US 4 8
Yurkovetskiy, Aleksandr V Littleton, US 39 329

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 16, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 16, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00